Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating expenses:
Research and development	$ 302,694	$ 376,767	$ 630,353	$ 622,915
General and administrative	581,032	533,935	982,409	1,092,235
Total operating expenses	883,726	910,702	1,612,762	1,715,150
Other income (expense):
Interest income	7	11	14	16
Change in valuation of derivative liability	800	(20,800)	1,300	(20,800)
Non-cash interest expense on convertible notes	(18,282)	(6,931)	(32,770)	(6,931)
Accretion to redemption value on convertible notes	(26,031)	(41,002)	(46,498)	(41,002)
Total other expense, net	(43,506)	(68,722)	(77,954)	(68,717)
Loss before income taxes	(927,232)	(979,424)	(1,690,716)	(1,783,867)
Provision for income taxes	2,400	0	2,400	2,400
Net loss	$ (929,632)	$ (979,424)	$ (1,693,116)	$ (1,786,267)
Basic loss per common share	$ (0.13)	$ (0.14)	$ (0.23)	$ (0.29)
Diluted loss per common share	$ (0.13)	$ (0.14)	$ (0.23)	$ (0.29)
Weighted average number of common shares outstanding – basic	7,235,447	7,222,403	7,235,447	6,228,900
Weighted average number of common shares outstanding – diluted	7,235,447	7,222,403	7,235,447	6,228,900